Bristol-Myers Squibb(BMY) ZACKS·2025-06-09 22:51Company Performance - Bristol Myers Squibb (BMY) closed at $49, reflecting a +1.22% increase from the previous day, outperforming the S&P 500's daily gain of 0.09% [1] - The stock has risen by 4.22% over the past month, compared to a 2.17% gain in the Medical sector and a 7.21% gain in the S&P 500 [1] Upcoming Financial Results - The company is expected to report an EPS of $1.67, indicating a 19.32% decline year-over-year [2] - Projected revenue for the upcoming quarter is $11.32 billion, reflecting a 7.19% decrease compared to the same quarter last year [2] Annual Estimates - For the annual period, earnings are anticipated to be $6.85 per share, representing a +495.65% change from the previous year, while revenue is projected at $46.31 billion, indicating a -4.11% change [3] Analyst Forecasts - Recent revisions to analyst forecasts for Bristol Myers Squibb should be monitored, as they often reflect changes in short-term business dynamics [4] - Positive estimate revisions are seen as a sign of optimism regarding the company's business outlook [4] Zacks Rank and Valuation - The Zacks Rank system currently rates Bristol Myers Squibb at 3 (Hold), with a recent 0.57% decline in the Zacks Consensus EPS estimate [6] - The company is trading at a Forward P/E ratio of 7.06, significantly lower than the industry average of 19.71, suggesting it is trading at a discount [7] PEG Ratio and Industry Ranking - Bristol Myers Squibb has a PEG ratio of 1.41, close to the industry average of 1.43 [8] - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [8][9]